These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. A case of chronic myelomonocytic leukemia complicated with spondyloarthritis. Matsumoto T; Saito T; Kohsaka H Mod Rheumatol; 2018 Mar; 28(2):373-375. PubMed ID: 26392142 [TBL] [Abstract][Full Text] [Related]
64. [Retrospective analysis of hemotherapy support in 226 cases of myelodysplastic syndromes]. Rubio-Félix D; Franco E; Giraldo P; Gimeno J; Cuesta I; Giralt M Sangre (Barc); 1994 Apr; 39(2):117-20. PubMed ID: 8059289 [TBL] [Abstract][Full Text] [Related]
65. Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. Xicoy B; Germing U; Jimenez MJ; Garcia O; Garcia R; Schemenau J; Pedro C; Luño E; Bernal T; González B; Strupp C; Ardanaz M; Kuendgen A; Cedena MT; Neukirchen J; Calabuig M; Brunet S; Medina A; Amigo ML; Ramos F; Callejas M; Díez-Campelo M; Bailén A; Collado R; Vicente A; Arnan M; Valcarcel D; Arilla MJ; Zamora L; Benlloch L; Sanz G Eur J Haematol; 2016 Jul; 97(1):33-8. PubMed ID: 26341961 [TBL] [Abstract][Full Text] [Related]
66. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article. Gao Y; Gong M; Zhang C; Kong X; Ma Y Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007 [TBL] [Abstract][Full Text] [Related]
67. Real-world data of chronic myelomonocytic leukemia: A chinese single-center retrospective study. Ma L; Jiang L; Yang W; Luo Y; Mei C; Zhou X; Xu G; Xu W; Ye L; Ren Y; Lu C; Lin P; Jin J; Tong H Cancer Med; 2021 Mar; 10(5):1715-1725. PubMed ID: 33559357 [TBL] [Abstract][Full Text] [Related]
68. Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation. Pan X; Gao M; Sun Y; Zhou Y; Wang K; Wang Y; Xu L; Zhang X; Huang X; Zhao XS Int J Lab Hematol; 2022 Jun; 44(3):510-517. PubMed ID: 35061336 [TBL] [Abstract][Full Text] [Related]
69. Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution. Breccia M; Latagliata R; Mengarelli A; Biondo F; Mandelli F; Alimena G Haematologica; 2004 Jul; 89(7):866-8. PubMed ID: 15257942 [TBL] [Abstract][Full Text] [Related]
70. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Loghavi S; Sui D; Wei P; Garcia-Manero G; Pierce S; Routbort MJ; Jabbour EJ; Pemmaraju N; Kanagal-Shamanna R; Gur HD; Hu S; Zuo Z; Medeiros LJ; Kantarjian HM; Khoury JD Blood Adv; 2018 Aug; 2(15):1807-1816. PubMed ID: 30054307 [TBL] [Abstract][Full Text] [Related]
72. Blastic Transformation in Mexican Population With Chronic Myelomonocytic Leukemia. Rivera Duarte A; Armengol Alonso A; Sandoval Cartagena E; Tuna Aguilar E Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):532-538. PubMed ID: 28842140 [TBL] [Abstract][Full Text] [Related]
73. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910 [TBL] [Abstract][Full Text] [Related]
74. [Rheumatologic manifestations of chronic myelomonocytic leukemia. Presentation of 2 cases]. Martino R; Nomdedéu JF; Brunet S; Sureda A; Montagut M; Domingo-Albós A Sangre (Barc); 1993 Dec; 38(6):493-6. PubMed ID: 8171386 [TBL] [Abstract][Full Text] [Related]
75. Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia? Elbæk MV; Sørensen AL; Hasselbalch HC Leuk Lymphoma; 2016 Aug; 57(8):1793-9. PubMed ID: 26879691 [TBL] [Abstract][Full Text] [Related]
76. Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Ogata H; Okamoto I; Yoshimoto G; Obara T; Ijichi K; Iwama E; Harada T; Akashi K; Nakanishi Y Respir Investig; 2017 Mar; 55(2):181-183. PubMed ID: 28274536 [TBL] [Abstract][Full Text] [Related]
77. Chronic myelomonocytic leukemia in the light of the WHO proposals. Germing U; Strupp C; Knipp S; Kuendgen A; Giagounidis A; Hildebrandt B; Aul C; Haas R; Gattermann N; Bennett JM Haematologica; 2007 Jul; 92(7):974-7. PubMed ID: 17606449 [TBL] [Abstract][Full Text] [Related]
78. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Such E; Germing U; Malcovati L; Cervera J; Kuendgen A; Della Porta MG; Nomdedeu B; Arenillas L; Luño E; Xicoy B; Amigo ML; Valcarcel D; Nachtkamp K; Ambaglio I; Hildebrandt B; Lorenzo I; Cazzola M; Sanz G Blood; 2013 Apr; 121(15):3005-15. PubMed ID: 23372164 [TBL] [Abstract][Full Text] [Related]
79. Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations. Kipfer B; Daikeler T; Kuchen S; Hallal M; Andina N; Allam R; Bonadies N Semin Hematol; 2018 Oct; 55(4):242-247. PubMed ID: 30502853 [TBL] [Abstract][Full Text] [Related]
80. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis. Shou LH; Cao D; Dong XH; Fang Q; Wu Y; Zhang Y; Fei JP; Xu BL PLoS One; 2017; 12(2):e0171608. PubMed ID: 28158286 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]